Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Cheng Huang

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Radiology|July 27, 2004
Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patientsSheung-Fat Ko, Tze-Yu Lee, Chung-Cheng Huang, et al.
Biomedical Journal|November 22, 2022
Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort studyShu-Min Lin, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 15, 2023
Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort studyShu-Min Lin, Chung-Shu Lee, Allen Chung-Cheng Huang, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
Infection and Drug Resistance|January 13, 2025
Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron VariantsHsin-I Cheng, Ko-Wei Chang, Bing-Chen Wu, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Radiology|July 27, 2004
Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patientsSheung-Fat Ko, Tze-Yu Lee, Chung-Cheng Huang, et al.
Biomedical Journal|November 22, 2022
Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort studyShu-Min Lin, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 15, 2023
Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort studyShu-Min Lin, Chung-Shu Lee, Allen Chung-Cheng Huang, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
Infection and Drug Resistance|January 13, 2025
Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron VariantsHsin-I Cheng, Ko-Wei Chang, Bing-Chen Wu, et al.
Thoracic Cancer|October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression controlShih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
Frontiers in Oncology|October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsPing-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology|August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancerAllen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers|January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor MutationChih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Pageof 10